CTLA4 and neoplasm: Importantly, in mouse models bearing primary as well as metastatic breast cancer, TMA-ARBs were shown to attenuate immunosuppression and potentiate anti-tumor T-cell activity, thereby enhancing anti-tumor response to anti-CTLA4 and anti-PD-1 combination ICI therapy.